VANCOUVER/SAN DIEGO, June 15 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI - News; OTC: MGIFF - News), a clinical-stage developer of drugs for infectious and degenerative diseases, has completed enrollment in a Phase IIb study of celgosivir (MX-3253) in combination with PEG-INTRON® (peginterferon alfa- 2b), and PEGETRON(TM) (peginterferon alfa-2b plus ribavirin) for the treatment of hepatitis C virus (HCV) infection in genotype 1 patients who were non- responders or partial responders to previous treatment with pegylated interferon-based therapy. A total of 57 subjects have been enrolled. The subjects will be treated for 12 weeks and results are expected to be available in October 2006. This study is being supported in part through an agreement with Schering-Plough.
